Meanwhile, mouse experiments demonstrated that transfer of tumor-specific CTLs with RGS1 knockdown in combination with PD-L1 could be a promising immunotherapeutic strategy for breast cancer [136]. This evidence concerns the gene RGS1 and breast carcinoma.